<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43552">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02539329</url>
  </required_header>
  <id_info>
    <org_study_id>1408060</org_study_id>
    <secondary_id>2014-A00636-41</secondary_id>
    <nct_id>NCT02539329</nct_id>
  </id_info>
  <brief_title>Characterization of Anti-FGFR3 Antibodies</brief_title>
  <official_title>Characterization of Sensory Neuropathies Associated With Anti-FGFR3 Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sensory neuronopathies affect sensory neuron in the posterior spinal ganglion. They are
      responsible for pain, balance disorder (ataxia) and the use of hands. They depend on
      multiple etiologies. In a retrospective study, the investigators showed that the anti-FGFR3
      antibody is a diagnostic marker of a subset of sensory neuronopathies. The investigators
      believe that other antibodies can be discovered in patients who remain seronegative
      changing.

      However, the study is retrospective and only a small number of patients could be identified.
      Several points therefore need to be clarified or confirmed in a second prospective study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In and out patients evaluated for a sensory neuropathy meeting the inclusion and
      non-inclusion criteria will be proposed to enter the study

      At inclusion the SSN diagnostic score is calculated and a blood sample is tested for
      anti-FGFR3 antibody.

      Follow up: Patients positive for anti-FGFR3 antibodies will be followed and evaluated
      clinically and electrophysiologically at 1, 6 and 12 months. A blood sample is taken at 6
      and 12 months.

      A subgroup of patients negative for anti-FGFR3 antibodies will be randomly selected for
      evaluation at 1, 6 and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of clinical and electrophysiological pattern of the neuropathy for patients with anti-FGFR3 antibodies (composite measure),</measure>
    <time_frame>6 months</time_frame>
    <description>Score to the Overall Disability Scale Score (ODSS), the Rankin Score, the International PrognosticScore (ISS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of clinical and electrophysiological pattern of the neuropathy for patients with anti-FGFR3 antibodies (composite measure),</measure>
    <time_frame>12 months</time_frame>
    <description>Score to the Overall Disability Scale Score (ODSS), the Rankin Score, the International PrognosticScore (ISS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description for patients with anti-FGFR3 antibodies of the immune context</measure>
    <time_frame>6 months</time_frame>
    <description>Levels of Antibodies anti-FGFR3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description for patients with anti-FGFR3 antibodies of the immune context</measure>
    <time_frame>12 months</time_frame>
    <description>Levels of Antibodies anti-FGFR3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient evolution during one year for patients with anti-FGFR3 antibodies to a control group of sensory neuropathy without antibodies</measure>
    <time_frame>12 months</time_frame>
    <description>Levels of Antibodies anti-FGFR3</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">465</enrollment>
  <condition>Sensory Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>patient</arm_group_label>
    <description>Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and positive for anti-FGFR3 antibodies. These patients will have Neurological assessment and Blood sample.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>Male or female patient aged 18 years with a clinically pure sensory peripheral neuropathy and negative for anti-FGFR3 antibodies</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurological assessment and Blood sample</intervention_name>
    <description>Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening</description>
    <arm_group_label>patient</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample for antibodies measure
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient group : patient with clinically pure sensory peripheral neuropathy and positive
        for anti-FGFR3 antibodies Control group :clinically pure sensory peripheral neuropathy and
        negative for anti-FGFR3 antibodies
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A :Patients Male or female patient aged 18 years or more

        Patients with a clinically pure sensory peripheral neuropathy including :

          -  idiopathic or dysimmune sensory neuronopathies

          -  idiopathic or dysimmune distal axonal sensory neuropathy

          -  sensory chronic inflammatory demyelinating polyradiculoneuropathy

          -  idiopathic or dysimmune small fiber neuropathies

          -  idiopathic or dysimmune trigeminal nerve neuropathy

          -  positive to antibodies anti-FGFR3

        B :Controls Male or female patient aged 18 years or more

        Patients with a clinically pure sensory peripheral neuropathy including :

          -  idiopathic or dysimmune sensory neuronopathies

          -  idiopathic or dysimmune distal axonal sensory neuropathy

          -  sensory chronic inflammatory demyelinating polyradiculoneuropathy

          -  idiopathic or dysimmune small fiber neuropathies

          -  idiopathic or dysimmune trigeminal nerve neuropathy

          -  negative to antibodies anti-FGFR3

        Exclusion Criteria:

          -  -Motor or sensory-motor neuropathies

          -  Genetic, toxic, paraneoplasic neuropathies

          -  Diabetic Neuropathy.

          -  Neuropathy with Anti-MAG or anti-ganglioside IgM.

          -  Pregnant or breastfeeding woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe ANTOINE, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU SAINT-ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Christophe ANTOINE, PhD</last_name>
    <email>j.christophe.antoine@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco ROTOLO</last_name>
    <email>Francesco.Rotolo@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain CREANGE, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Alain CREANGE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmeline LAGRANGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmeline LAGRANGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MAGY, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent MAGY, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe VIAL, Md PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahram ATTARIAN</last_name>
    </contact>
    <investigator>
      <last_name>Shahram ATTARIAN, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann PEREON, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Yann PEREON, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de NICE</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela PUMA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Angela PUMA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital BICETRE</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David ADAMS, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>David ADAMS, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>: Jean-Marc LEGER, MD</last_name>
    </contact>
    <investigator>
      <last_name>: Jean-Marc LEGER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine GUÉGUEN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane G. MATHIS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane MATHIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Christophe ANTOINE, PhD</last_name>
      <email>j.christophe.antoine@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Christophe ANTOINE, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chu Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andoni ECHANIZ LAGUNA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andoni ECHANIZ LAGUNA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 11, 2017</lastchanged_date>
  <firstreceived_date>July 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropathy</keyword>
  <keyword>antibodies antiFGFR3</keyword>
  <keyword>Biological diagnostic criteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
